Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00329
|
|||||
| Drug Name |
Glipizide
|
|||||
| Synonyms |
1-Cyclohexyl-3-((p-(2-(5-methylpyrazinecarboxamido)ethyl)phenyl)sulfonyl)urea; 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea; Aldiab; Alphapharm Brand of Glipizide; CP 28,720; CP 28720; CP-28720; Digrin; Dipazide; G-117; Glibenese; Glibenese Brand of Glipizide; Glibetin; Glican; Glide; Glidiab; Glidiazinamide; Glipid; Glipizida; Glipizida [INN-Spanish]; Glipizide (USP/INN); Glipizide Extended-Release Tablets; Glipizide Kenfarma Brand; Glipizide [USAN:BAN:INN]; Glipizidum; Glipizidum [INN-Latin]; Gluco-Rite; Glucolip; Glucotrol; Glucotrol (TN); Glucotrol XL; Glucotrol XL, Glucotrol, Glipizide; Glucozide; Glupitel; Glupizide; Glyde; Glydiazinamide; Glypidizine; K 4024; K-4024; K4024; KS-1068; Kenfarma Brand of Glipizide; Lacer Brand of Glipizide; Lilly Brand of Glipizide; Melizide; Metaglip; Mindiab; Minidab; Minidiab; Minodiab; N-(2-{4-[(cyclohexylcarbamoyl)sulfamoyl]phenyl}ethyl)-5-methylpyrazine-2-carboxamide; N-(4-(beta-(5-Methylpyrazine-2-carboxamido)ethyl)benzenesulphonyl)-N'-cyclohexylurea; N-[2-(4-{[(cyclohexylcarbamoyl)amino]sulfonyl}phenyl)ethyl]-5-methylpyrazine-2-carboxamide; N-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-5-methylpyrazine-2-carboxamide; Napizide; Ozidia; Pfizer Brand 2 of Glipizide; PfizerBrand 1 of Glipizide; Samarium(III) ionophore I; Semiglynase; Sucrazide; TK 1320
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Diabetes [ICD11:5A10-5A14] | Approved | [1] | |||
| Therapeutic Class |
Hypoglycemic Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H27N5O4S
|
|||||
| Canonical SMILES |
CC1=CN=C(C=N1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
|
|||||
| InChI |
InChI=1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)
|
|||||
| InChIKey |
ZJJXGWJIGJFDTL-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 29094-61-9
|
|||||
| Pharmaceutical Properties | Molecular Weight | 445.5 | Topological Polar Surface Area | 139 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 7 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 6 | |||
| XLogP |
1.9
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321342
,11111214
,11112714
,11119955
,11120443
,11120931
,11121414
,11121894
,11147038
,11362483
,11365045
,11367607
,11370237
,11370238
,11373208
,11375769
,11466159
,11467279
,11485877
,14906210
,17405183
,24277839
,24858438
,25819918
,26751569
,26751570
,29222611
,3153201
,46505865
,47290874
,47290875
,47515059
,47588733
,47662000
,47810481
,47885136
,49698363
,49836250
,50060598
,50100247
,50104189
,50104190
,50104191
,5043710
,53777727
,53787230
,7847401
,7979413
,8152212
,855947
|
|||||
| ChEBI ID |
ChEBI:5384
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BSEP | Transporter Info | Bile salt export pump | Substrate | [2] | |
| References | ||||||
| 1 | Glipizide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.